Policy · 2026-05-06
Consumer Choice Center: FDA's Case for Banning 7-OH "Doesn't Survive Contact with the Data"
Source: Consumer Choice Center
Why it matters
A prominent free-market policy organization is challenging the scientific basis for the FDA's push to schedule 7-OH as a Schedule I substance, citing toxicologist testimony, pharmacology research, and adverse event data that the authors argue do not support emergency prohibition.
The big picture
The FDA has formally asked the DEA to classify 7-OH as Schedule I — the most restrictive drug tier — alongside heroin and LSD. Proponents of the ban cite 7-OH's potency relative to morphine and link it to overdose deaths. Critics, including academic toxicologists and now consumer advocates, argue the evidence is mischaracterized and that prohibition will push users toward more dangerous alternatives.
Key findings
- After roughly 2 billion servings of 7-OH sold since 2023, the FDA's adverse event database logged approximately 100 reports — about one per 20 million servings
- Research at Memorial Sloan-Kettering found 7-OH does not induce respiratory depression, the mechanism responsible for classical opioid overdose deaths
- Only 2.7–3% of an oral dose of 7-OH survives first-pass metabolism, sharply limiting brain exposure compared to injected opioids
- Harvard toxicologist Dr. Edward Boyer testified there is no overdose death signal from 7-OH consumed in isolation; America's Poison Centers has not reported a single confirmed 7-OH-only fatality
- Author argues some lobbying for Schedule I listing comes from legacy kratom manufacturers seeking to eliminate 7-OH market competitors — what the author calls a "boomerang effect"
What they say
"A signal arising from overdose death from 7-hydroxymitragynine is absent." — Dr. Edward Boyer, Harvard-trained medical toxicologist, testifying before the Ohio House Agriculture Committee
Bottom line
Free-market analysts and academic toxicologists are challenging the FDA's case against 7-OH, arguing the substance's pharmacology and real-world adverse event record do not support Schedule I classification alongside heroin.